Clinical Trial Update: PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update evaluating PHA-739358 for patients with chronic myeloid leukemia that relapsed after imatinib mesylate or c-ABL therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• PHA-739358

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Leukemia | Phase 2 | Status: UNKNOWN